Introduction

Possesses nearly 20 years of clinical oncology experience within China's top-tier Grade A tertiary hospitals. Highly experienced in precision treatment fields such as  minimally invasive interventional therapy for benign and malignant tumors, chemotherapy, and combined targeted-immunotherapy. Long-term focus on complex cancers including lung cancer, liver cancer, colon cancer, gastric cancer, esophageal cancer, ovarian cancer, and cervical cancer. Advocates for the Multidisciplinary Team model, leveraging rich and personalized comprehensive diagnostic and therapeutic experience. Accurately formulates individualized treatment plans based on patient condition and molecular pathological characteristics, aiming to enhance efficacy while improving patient quality of life and treatment experience.

Medical Experience

Member, Hepatobiliary and Pancreatic Tumors Professional Committee, Guangzhou Anti-Cancer Association

Member, Tumor Immunotherapy Professional Committee, Guangdong Pharmaceutical Association

Member, Interventional Medicine Professional Committee, Guangzhou Medical Association

Member, Liver Cancer Professional Committee, Tumor Rehabilitation Branch, Chinese Geriatrics Society

Member, Thyroid Nodule and Tumor Prevention and Control Professional Committee, China Health Care Association

Academic Achievements

Published 5 papers in core medical journals and 1 SCI-indexed paper.

Awarded 1 Third Prize for Military Medical Achievements.

Participated in 1 provincial-level government-funded research project.

Research Paper

Published an article titled Treatment of Mid-late Stage NSCLC Using Sodium Cantharidinate/ Vitamin B6/ GP Regimen in Clinic in an SCI-indexed journal (Journal of Cancer Research and Therapeutics, IF=1.5).

Awarded 3rd prize in International Journal of Oncology essay contest (Sep 2013, first author) for clinical research on Sodium Cantharidinate/ Vitamin B6 Injection Combined with GP Regimen for Mid-late Stage Lung Cancer.

Received 3rd prize for military medical achievements (Mar 2014) for research on Nedaplatin in Advanced Nasopharyngeal Carcinoma Treatment.

Research Area

Integrated Minimally Invasive Therapy for Tumors

Multidisciplinary Team (MDT) Precision Personalized Diagnosis and Treatment Model

Application of Combined Targeted and Immunotherapy Strategies in Oncology

*Surgery, in addition to the appropriate chemotherapy and radiotherapy, are effective in treating early cancer, but certain patients in late stage of cancer may not be tolerate surgery well as they can be relatively weak. A combination of carefully planned minimally invasive therapy, chemotherapy or radiotherapy can effectively reduce the side effects and discomfort of treatment and may help patient get better efficacy.